Experts Want FDA to Expand Who Qualifies for TRT in 2026 — Could This Open the Door for Millions More Men?

A group of leading men's health specialists has published recommendations urging the FDA to fundamentally restructure how testosterone replacement therapy (TRT) is prescribed in the United States. The proposed changes could dramatically expand access to treatment for millions of men who currently fall outside FDA-approved labeling — but critics warn that wider access must come with robust safety monitoring.

The recommendations, published in the January 2026 issue of The Journal of Clinical Endocrinology, argue that the current FDA labeling for TRT is too restrictive and doesn't align with the latest clinical evidence on testosterone deficiency and its treatment.

What's Changed in the Proposed Guidelines

Currently, FDA-approved TRT labeling restricts treatment primarily to men with specific medical conditions that cause hypogonadism — including genetic disorders, testicular injury, or pituitary gland problems. The new recommendations propose expanding eligibility to include any man who meets two criteria:

• Documented low testosterone levels (generally defined as total testosterone below 300 ng/dL on morning fasting blood tests, confirmed on at least two separate occasions)
• Documented symptoms of testosterone deficiency — including fatigue, reduced libido, erectile dysfunction, depressed mood, decreased muscle mass, or cognitive changes

This is a meaningful expansion. Under current labeling, a 45-year-old man with fatigue, low libido, and testosterone of 280 ng/dL — but without a specific underlying medical condition — would typically not qualify for FDA-approved TRT. Under the proposed guidelines, he would.

Why Now?

The push for expanded eligibility reflects several converging factors:

1. Evolving clinical understanding. Recent research suggests that the traditional "normal" range for testosterone (300–1,000 ng/dL) may be too broad. Many men with levels in the lower portion of this range experience genuine symptoms that improve with TRT.

2. The telehealth revolution. Online TRT clinics have exploded in popularity, with companies like Manual, HerO Health, and Alpha MD serving hundreds of thousands of patients. These providers often operate in a gray area relative to FDA labeling — treating patients who meet clinical criteria but not strict labeling requirements.

3. Patient advocacy. Men's health organizations have argued for years that the current restrictions create barriers to care and push men toward unregulated supplements or black-market anabolic steroids.

What This Means for Patients

If the FDA adopts all or part of these recommendations, the practical impact could be significant:

Easier online access. Telehealth TRT providers would no longer need to navigate labeling ambiguity. Patients could get clear, FDA-aligned prescriptions from online clinics without concern about regulatory gray areas.

Lower costs through competition. With more providers able to offer FDA-compliant treatment, competition could drive prices down. Monthly TRT costs through telehealth platforms typically range from $50–$150/month (including medication and monitoring), compared to $200–$400+ through traditional specialty clinics.

Insurance coverage expansion. Many insurers currently deny TRT claims based on the specific FDA labeling restrictions. Broader labeling could force insurers to cover treatment for a larger patient population.

Safety Concerns Remain

Not everyone is celebrating. Some endocrinologists have raised concerns about expanding TRT access without parallel investment in safety monitoring:

Cardiovascular risk. The relationship between TRT and cardiovascular events remains debated. Earlier studies suggested increased risk, but more recent research — including large retrospective analyses published in 2024 and 2025 — has largely assuaged these concerns in men without pre-existing cardiovascular disease. Still, baseline cardiovascular screening remains essential.

Prostate monitoring. TRT can stimulate prostate growth, and men on TRT require regular PSA monitoring and digital rectal exams. Expanded access without robust monitoring protocols could miss early prostate cancer or significant benign prostatic hyperplasia.

Hematocrit elevation. TRT increases red blood cell count, which can thicken blood and increase clotting risk. Regular hematocrit monitoring is standard in TRT protocols, but broader access could mean more men skipping this crucial safety check.

The authors of the new recommendations acknowledge these concerns and propose mandatory baseline and follow-up screening protocols for any patient initiating TRT under expanded eligibility.

How to Access TRT Today

Even before any FDA label change, men can access TRT through multiple pathways:

Telehealth platforms. Online TRT clinics have proliferated, offering convenient access to prescribing physicians. Most operate in compliance with state medical boards and offer treatment based on clinical criteria similar to those in the proposed recommendations. Top options include Manual, HerO Health, and Alpha MD.

Traditional urology or endocrinology. In-person specialists can prescribe TRT and provide comprehensive metabolic workups. This route offers more hands-on monitoring but typically costs more and has longer wait times.

Key steps before starting:

1. Get baseline bloodwork: total testosterone (morning fasting), free testosterone, estradiol, LH, FSH, TSH, CBC, CMP, lipid panel, and PSA (for men over 40)
2. Discuss symptoms honestly with a provider
3. Ensure a monitoring plan is in place (follow-up labs at 3, 6, and 12 months, then annually)

What Comes Next

The FDA has not yet indicated whether it will adopt the proposed labeling changes. A public comment period is expected to open in Q2 2026, with a potential decision by late 2026 or early 2027.

In the meantime, men interested in TRT have more options than ever. The telehealth model has already effectively expanded access beyond what current FDA labeling permits — with or without a formal label change.

How do I know if I have low testosterone?

The only way to diagnose low testosterone is through blood testing. A morning (fasting) total testosterone level below 300 ng/dL is generally considered low, though your provider should confirm this with a second test. Symptoms like fatigue, low libido, erectile dysfunction, depression, and reduced muscle mass are also important indicators. See our complete guide to low-T symptoms for a fuller picture.

Can I get TRT through telehealth?

Yes. Telehealth TRT clinics operate in most states and can prescribe testosterone based on clinical criteria. These platforms typically offer online consultations, at-home lab testing, and medication delivery. Most are affordable ($50–$150/month) and have licensed physicians who can prescribe legally in your state.

Is TRT safe?

TRT is generally considered safe for men without pre-existing cardiovascular disease or prostate cancer, when properly monitored. Key safety protocols include baseline cardiovascular screening, PSA monitoring, and regular blood work to check hematocrit, estradiol, and testosterone levels. Working with a knowledgeable provider who follows evidence-based protocols is essential.